Central venous line complications with chronic ambulatory infusion of XXXX analogues in pediatric @entity1 with @entity120 .

@entity1 @entity120 @entity4770 @entity281 @entity1211
Chronic infusion of @entity4770 (PGI2) via a Broviac central venous line (CVL) is attended by risk of CVL-related complications, but we know of only one report regarding CVL-associated @entity281 ( @entity281 ) with PGI2 in @entity1 and none regarding other complications. We conducted a retrospective cohort study involving pediatric @entity1 with @entity120 treated with chronic intravenous infusion of PGI2 at Boston @entity1 's Hospital and determined the rate (per 1,000 line-days) of various CVL-related complications. We also determined how often complications necessitated line replacement and hospitalization, time to replacement of CVLs, and interpatient variability in the incidence of complications. From 1999 until 2014, 26 @entity1 meeting follow-up criteria had PGI2 infusion, representing 43,855 line-days; mean follow-up was 56 months (range, 1.4-161 months). The CVL complication rates (per 1,000 line-days) were as follows: CVL- @entity281 , 0.25; superficial line infection, 0.48; impaired integrity, 0.59; occlusion, 0.09; and malposition, 0.32. The total complication rate was 1.73 cases per 1,000 line-days. All CVL- @entity281 and malposition cases were treated with CVL removal and replacement. Of CVLs with impaired integrity, 23 could be repaired and 3 required replacement. Six of 21 superficial @entity1211 required replacement of the CVL. Three of 4 occluded CVLs were replaced. CVL complications occasioned 65 hospitalizations. There was marked interpatient variability in the rate of complications, much but not all of which appeared to be related to duration of CVL placement. We conclude that non- @entity281 complications are very significant and that efforts to teach and emphasize other aspects of line care are therefore very important.
